Latest updates on chronic viral hepatitis B

Creative Commons License

İDİLMAN R., Karakaya F.

MARMARA MEDICAL JOURNAL, cilt.29, ss.33-37, 2016 (ESCI) identifier identifier

  • Yayın Türü: Makale / Derleme
  • Cilt numarası: 29
  • Basım Tarihi: 2016
  • Doi Numarası: 10.5472/mmjsi.2901.07
  • Dergi Adı: MARMARA MEDICAL JOURNAL
  • Derginin Tarandığı İndeksler: Emerging Sources Citation Index (ESCI), Scopus, TR DİZİN (ULAKBİM)
  • Sayfa Sayıları: ss.33-37
  • Anahtar Kelimeler: Chronic hepatitis B, Nucleos(t)ide analog, Entecavir, Tenofovir disoproxil fumarate
  • Ankara Üniversitesi Adresli: Evet

Özet

Hepatitis B virus (HBV) remains a major cause of liver-related morbidity and mortality in Turkey and all over the world. Two different types of antiviral agents can be used in the treatment of chronic hepatitis B (CHB). Conventional (IFN) or pegylated interferon alpha (PegIFN), nucleoside [lamivudine (LMV), telbivudine, emtricitabine, entecavir (ETV)] and nucleotide analogs [adefovir dipivoxil (ADV)] and tenofovir disoproxil fumarate (TDF)]. Antiviral agent must ensure a degree of HBV viral suppression and will lead to biochemical, serological remission and histological improvement. Current treatment strategies are discussed in present brief report.